- Home
- FINW vs STTK Comparison
FINW vs STTK Comparison
Compare FINW & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- STTK
- Stock Information
- Founded
- FINW 1999
- STTK 2016
- Country
- FINW United States
- STTK United States
- Employees
- FINW N/A
- STTK N/A
- Industry
- FINW Commercial Banks
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- STTK Health Care
- Exchange
- FINW Nasdaq
- STTK Nasdaq
- Market Cap
- FINW 196.2M
- STTK 37.6M
- IPO Year
- FINW 2021
- STTK 2020
- Fundamental
- Price
- FINW $15.67
- STTK $0.83
- Analyst Decision
- FINW Buy
- STTK Hold
- Analyst Count
- FINW 4
- STTK 4
- Target Price
- FINW $20.75
- STTK $3.00
- AVG Volume (30 Days)
- FINW 76.0K
- STTK 401.7K
- Earning Date
- FINW 07-24-2025
- STTK 07-31-2025
- Dividend Yield
- FINW N/A
- STTK N/A
- EPS Growth
- FINW N/A
- STTK N/A
- EPS
- FINW 0.91
- STTK N/A
- Revenue
- FINW $72,056,000.00
- STTK $4,606,000.00
- Revenue This Year
- FINW $38.17
- STTK N/A
- Revenue Next Year
- FINW $18.44
- STTK N/A
- P/E Ratio
- FINW $17.21
- STTK N/A
- Revenue Growth
- FINW 7.66
- STTK 69.65
- 52 Week Low
- FINW $10.29
- STTK $0.69
- 52 Week High
- FINW $20.94
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- FINW 66.33
- STTK 39.19
- Support Level
- FINW $13.81
- STTK $0.77
- Resistance Level
- FINW $14.37
- STTK $0.91
- Average True Range (ATR)
- FINW 0.55
- STTK 0.08
- MACD
- FINW 0.22
- STTK -0.02
- Stochastic Oscillator
- FINW 89.53
- STTK 16.23
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.